Everence Capital Management Inc. Takes Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Everence Capital Management Inc. bought a new position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 3,490 shares of the company’s stock, valued at approximately $476,000.

Other institutional investors have also added to or reduced their stakes in the company. Ashton Thomas Private Wealth LLC purchased a new position in shares of Neurocrine Biosciences in the 2nd quarter worth about $28,000. Blue Trust Inc. boosted its stake in Neurocrine Biosciences by 171.9% in the third quarter. Blue Trust Inc. now owns 348 shares of the company’s stock worth $40,000 after buying an additional 220 shares in the last quarter. Plato Investment Management Ltd grew its position in Neurocrine Biosciences by 44.1% during the second quarter. Plato Investment Management Ltd now owns 425 shares of the company’s stock valued at $59,000 after acquiring an additional 130 shares during the last quarter. Truvestments Capital LLC purchased a new position in shares of Neurocrine Biosciences during the third quarter worth approximately $63,000. Finally, True Wealth Design LLC lifted its holdings in shares of Neurocrine Biosciences by 11,740.0% in the 3rd quarter. True Wealth Design LLC now owns 592 shares of the company’s stock worth $68,000 after acquiring an additional 587 shares during the last quarter. Institutional investors own 92.59% of the company’s stock.

Analysts Set New Price Targets

Several analysts have weighed in on the stock. BMO Capital Markets lowered their price target on shares of Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating for the company in a research note on Thursday, October 17th. Wedbush restated an “outperform” rating and set a $148.00 target price on shares of Neurocrine Biosciences in a report on Monday, December 16th. HC Wainwright restated a “buy” rating and set a $190.00 price target on shares of Neurocrine Biosciences in a research report on Monday, December 16th. StockNews.com lowered Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, November 1st. Finally, Raymond James reaffirmed an “outperform” rating and issued a $155.00 target price on shares of Neurocrine Biosciences in a research note on Thursday, October 10th. Five analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $166.29.

Insider Activity at Neurocrine Biosciences

In other Neurocrine Biosciences news, insider Jude Onyia sold 2,331 shares of the firm’s stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $126.29, for a total transaction of $294,381.99. Following the completion of the sale, the insider now directly owns 15,449 shares in the company, valued at approximately $1,951,054.21. This trade represents a 13.11 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Ingrid Delaet sold 1,091 shares of the company’s stock in a transaction that occurred on Tuesday, December 17th. The stock was sold at an average price of $135.00, for a total transaction of $147,285.00. Following the completion of the transaction, the insider now owns 2,507 shares in the company, valued at approximately $338,445. This represents a 30.32 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 3,694 shares of company stock valued at $479,230 in the last 90 days. Corporate insiders own 4.30% of the company’s stock.

Neurocrine Biosciences Stock Performance

Shares of NBIX opened at $138.10 on Monday. The firm’s 50-day simple moving average is $128.11 and its two-hundred day simple moving average is $130.81. Neurocrine Biosciences, Inc. has a fifty-two week low of $110.95 and a fifty-two week high of $157.98. The stock has a market cap of $13.98 billion, a PE ratio of 37.02 and a beta of 0.33.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.